Previous 10 | Next 10 |
2024-01-09 09:00:00 ET Summary Chris DeMuth Jr. discusses his position in uranium and his belief that nuclear energy will play a significant role in the future of energy production. He also updates us on SHF Holdings, a fintech company serving the cannabis industry, and predicts i...
2024-01-08 12:31:33 ET More on Arbutus Biopharma Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript Putting Arbutus Biopharma Back In The Spotlight Arbutus Biopharma GAAP EPS of -$0.12 misses by $0.01, revenue of $4.66M misses by $0.06M, reduces 24...
Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024 Initiation of a third Phase 2a clinical trial evaluating imdusiran and an approved PD-L1 monoclonal antibody...
2023-12-04 16:36:31 ET Gainers: GitLab ( GTLB ) +16% . EyePoint Pharmaceuticals ( EYPT ) +6% . Travere Therapeutics ( TVTX ) +3% . AST SpaceMobile ( ASTS ) +3% . Arbutus Biopharma Corporation ( ABUS ) +2% . Losers: ...
Initial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline. In HBV003, 31% of participants with screening HBsAg level of ≤200 IU/mL had >1 log HBsAg reductions. VTP-300 was generally well...
The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline Preliminary data in subset of patients given imdusiran and then VTP-300 show early signs of immune activation WARMINSTER, Pa. and OXFORD, United Kingdom, ...
2023-11-07 11:06:05 ET Arbutus Biopharma Corporation. (ABUS) Q3 2023 Earnings Conference Call November 07, 2023, 08.45 AM ET Company Participants Lisa Caperelli - VP of IR Bill Collier - President, CEO and Director David Hastings - CFO and CAO Karen Sims - Ch...
2023-11-07 08:47:44 ET More on Arbutus Biopharma Putting Arbutus Biopharma Back In The Spotlight Alnylam sends Arbutus lower after FDA snub for amyloidosis drug For further details see: Arbutus Biopharma says its CEO William Collier will retire
2023-11-07 07:36:28 ET More on Arbutus Biopharma Putting Arbutus Biopharma Back In The Spotlight Arbutus Biopharma Corporation 2023 Q2 - Results - Earnings Call Presentation Alnylam sends Arbutus lower after FDA snub for amyloidosis drug Arbutus ends developm...
Multiple data presentations upcoming at AASLD – The Liver Meeting®, including preliminary data from Phase 2a clinical trial combining imdusiran, our RNAi therapeutic, with VTP-300, an HBV antigen-specific immunotherapy Dosing continues in two Phase 2a combination clinical tr...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...